Abstract
We used a noninvasive electrochemical quantitative assay for IgG antibodies to SARS-CoV-2 S1 in saliva to investigate the kinetics of antibody response in a community-based population who had received either the Pfizer or Moderna mRNA-based vaccines. Samples were received from a total of 97 individuals including a subset of 42 individuals who collected samples twice-weekly for 3 months or longer. In all, 840 samples were collected and analyzed. In all individuals, salivary antibody levels rose sharply in the 2-week period following their second vaccination, with peak antibody levels being at 10-20 days post-vaccination. We observed that 20%, 10% and 2.4% of individuals providing serial samples had a 90%, 95%, and 99% drop respectively from peak levels during the duration of monitoring and two patients fell to pre-vaccination levels (5%). The use of non-invasive quantitative salivary antibody measurement can allow widespread, cost-effective monitoring of vaccine response.
Article Summary Line COVID-19 antibodies were measured in saliva and 20% of vaccinated subjects experienced a 90% drop in peak antibody levels over the course of monitoring.
Competing Interest Statement
D. Wong is consultant to Colgate-Palmolive, Mars Wrigley and GSK. D. Wong also have equity in Liquid Diagnostics and RNAmeTRIX. DW, CS, MT, RB are shareholders in Liquid Diagnostics LLC. MT is a paid consultant of Liquid Diagnostics LLC. RB is a consultant to Amgen, Bristol Myers Squibb.
Funding Statement
This study was funded by Liquid Diagnostics, LLC. Michael Tu is a salaried employee of Liquid Diagnostics. Richard Bender and Charles Strom are unpaid officers of Liquid Diagnostics
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Western Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
List of keywords. There is no limit on the number of keywords. Use terms listed in the Medical Subject Headings from Index Medicus.
Data Availability
Data will be available on demand
